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Abstract 
Thiolated polymers are a promising new group of excipients, but their stability against atmospheric 
oxidation has not been investigated in detail, and only a few efforts have been made to improve 
their stability. The oxidation of the thiol groups in solutions of thiolated polymers may result in a 
decrease of mucoadhesion and unpredictable in situ gelation. The aims of our work were to study 
the stability of aqueous solutions of thiolated polymers and the effects of stabilizing agents. 
We investigated thiolated poly(aspartic acid) polymers stabilized with dithiothreitol, glutathione 
or acetylcysteine. The effects of these antioxidants on the gel structure, mucoadhesion and drug 
release were determined by means of scanning electron microscopy, swelling, rheology, adhesion 
and drug release tests. It was concluded that the stability of polymer solutions containing 
antioxidants is sufficient for one day. Polymers stabilized with dithiotreitol demonstrated fast 
swelling and drug release, but weaker mucoadhesion as compared with the other samples. 
Polymers stabilized with glutathione displayed the weakest cohesive properties, resulting in fast 
and uncontrolled drug release and moderate mucoadhesion. Acetylcysteine-stabilized polymers 
exhibited an optimum cross-linked structure, with free thiol groups ensuring polymer-mucin 
interactions, resulting in the best mucoadhesive properties. 
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1. Introduction 
In 1995, the International Pharmaceutical Excipient Council defined excipients as substances 
other than the active drug substance or finished dosage form, which are appropriately evaluated 
for safety and are included in a drug delivery system to aid the processing of the drug delivery 
system during its manufacture. They can protect, support and enhance the stability, and 
bioavailability of the drug, or they can improve the patient acceptability, assist in product 
identification, or enhance any other attributes of the overall safety and effectiveness of the drug 
delivery system during storage or use [1]. However, excipients are neither inert nor inactive 
substances, and they can also cause adverse reactions [2, 3]. 
Thiolated polymers are second-generation mucoadhesive polymers, which can be potentially 
applied as excipients in sustained drug delivery. They are able to form covalent bonds with the 
cysteine-rich sub-domains of the mucus glycoproteins, and also hydrogen-bonds and van der 
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Waals’ forces. Thiolated polymers can increase the residence time on the mucosal surface and 
improve the bioavailability of the drug [4]. Additionally they have several other advantageous 
properties, such as their in situ gelling, enzyme-inhibitory capabilities, permeation-enhancing 
effect and efflux pump inhibition [5-7]. All these advantageous properties have already been 
described, but little information is available about the stability of thiolated polymers, which is an 
important factor in drug delivery formulation.  
Earlier studies [8, 9] revealed the lower stability of thiolated polymers in solutions as a result 
of thiol oxidation. In the oxidation process, inter- and intramolecular disulfide bonds are formed, 
limiting the permeation enhancement and mucoadhesive character of the polymers. The oxidation 
of thiol groups is faster at pH ≥ 6 because of the increase in the concentration of negative thiolate 
anions, -S−, which are more capable of oxidation.   
There are two possibilities for the stabilization of thiolated polymers in solution: 1) the use of 
reducing agents (antioxidants) or 2) the protection of the thiol groups by the formation of disulfide 
bonds in a controlled way [8-10]. 
The addition of a reducing agent during or after the polymer synthesis ensures the stability of 
the thiol groups in solution, providing free thiol groups for better mucoadhesion and permeation. 
In earlier studies, 2-mercaptoethanol [8], dithiothreitol (DTT), sodium borohydride [11]. 
hydroxylamine [12], EDTA [13] and sodium cyanoborohydride [14] have been used to avoid the 
oxidation of thiol groups.  
In thiol group protection, the thiol groups are shielded from oxidative effects by disulfide bonds. 
In earlier studies, this type of protection was performed with 6-mercaptonicotinamide [10,15] 2-
mercaptonicotinamide [16,17] or 3-methyl-1-phenylpyrazole-5-thiol [18]. Thanks to the addition 
of these protective agents, the thiolated polymers have improved stability and maintain their 
mucoadhesive and other properties [10]. A disadvantage of this method is the longer synthetic 
pathway. 
In our work, thiolated poly(aspartic acid) (ThioPASP) was used. PASP is a biocompatible, 
biodegradable, non-toxic polymer and does not generate immunogenicity [19, 20]. ThioPASP 
polymers are designed to be used in ophthalmic therapy as liquid formulations which display a 
solution-to-gel transition [21] due to disulfide formation at the ocular surface. This type of in situ 
gelation permits the development of a formulation of ThioPASP that is easy to administer as 
solution and has a prolonged residence time thanks to the mucoadhesive gel formation. However, 
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the undesired formation of disulfides under atmospheric conditions might deteriorate the swelling, 
adhesive and related properties of the polymer. Accordingly, in this study the solutions of 
ThioPASP were stabilized by the addition of three types of reducing agents: DTT, glutathione 
(GSH) and acetylcysteine (ACC). DTT is a strong, while GSH and ACC are considered to be 
weaker reducing agents [22].  
DTT has been a preferred reagent for the reduction of disulfide bonds for decades, even though 
it is expensive and unstable in solution [22, 23]. GSH can be found in all parts of cells, where its 
main function is to provide the main redox buffer and to protect cells from oxidative stress. Thanks 
to the high concentration of GSH in the cytosol, protein disulfide bonds are rarely formed [24] 
ACC has low toxicity and mild side-effects when administered intravenously, orally or by 
inhalation [25]. It is used in ophthalmic therapy as an excipient and also as an active 
pharmaceutical ingredient (API). It has favourable effects in corneal diseases such as 
keratoconjuctivitis sicca, filamentary keratitis or corneal ulcers [26]. DTT was chosen as a 
reference antioxidant, and GSH and ACC as compounds present in cells or used pharmaceutically; 
they are considered to be safe and non-toxic, especially in ocular therapy.  
The aim of our work was to determine the effects of the antioxidant agent on the polymer 
stability in aqueous solution, the final gel structure and properties such as their swelling capability, 
rheology, mucoadhesion and drug release. In possession of the results, we planned to find the 
optimal stabilizing agent for the ThioPASP polymers, which will provide an appropriate structure 
for mucoadhesion and drug release to ensure a potential in situ gelling ocular drug delivery system.  
 
2. Materials and methods 
2.1. Materials 
Previously synthetized ThioPASP polymers were used [21, 27] and the molar ratio of thiolated 
repeating units to the total number of repeating units was calculated to be 10% n/n.. Polymer 
samples were prepared with different stabilizing agents. The following reducing agents were added 
to the samples before the lyophilization procedure: DTT (Merck, Darmstadt, Germany), GSH 
(Merck, Darmstadt, Germany) and ACC (Reanal, Budapest, Hungary). The amount of antioxidant 
was 1% w/w of the polymer in each case. The polymer samples stabilized with these reducing 
agents are referred to below as ThioPASP/DTT, ThioPASP/GSH and ThioPASP/ACC, 
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respectively.Chemical structures of the polymer and the antioxidants are included in supporting 
information for better understanding. 
As a model oxidant, 1 M NaBrO3 solution was used. A phosphate-buffered saline (PBS) 
solution of pH-= 7.4 was prepared by dissolving 8 g dm-3 NaCl, 0.2 g dm-3 KCl, 1.44 g dm-3 
Na2HPO4·2H2O and 0.12 g dm-3 KH2PO4 in distilled water; the pH was adjusted with 0.1 M HCl. 
Lachrymal fluid of pH = 7.4 was prepared by dissolving 2.2 g dm-3 NaHCO3, 6.26 g dm-3 NaCl, 
1.79 g dm-3 KCl, 96.4 mg dm-3 MgCl2·6H2O and 73.5 mg dm-3 CaCl2·H2O in distilled water; the 
pH was adjusted with 1 M HCl [27] 
Mucin (porcine gastric mucin type II, for mucoadhesion measurements), and sodium diclofenac 
(SD, for drug release measurements) were purchased from Sigma Aldrich (USA, St Louis, MO). 
  
2.2. Determination of the concentration of free thiol groups 
The stability of polymer in presence of antioxidant was investigated in aqueous solution 
(pH = 7.4 PBS solution), which were stored at -20 °C, 4 °C and 25 °C. The stability of polymer 
was indicated by the free thiol content. The percentage of free thiol groups was determined on 0, 
1, 7, 14 and 28 days. For each measuring point, the solutions containing 10% w/w of polymer with 
different polymer-antioxidant combinations were prepared in triplicate. The thiol content of the 
polymer solutions containing stabilizing agent was determined by Ellman’s assay similarly to the 
method described earlier for non-stabilized ThioPASP [28]. At pre-determined time intervals, one 
polymer solution (10% w/w of polymer; PBS pH = 7.4) of each composition (ThioPASP/DTT, 
ThioPASP/GSH and ThioPASP/ACC) was diluted with buffer solution (pH = 8) to yield a final 
polymer concentration of approximately 0.05% w/v at room temperature and analysed 
immediately after dilution. 180 µl of each sample solution was diluted in 1800 µl aqueous buffer 
solution (pH = 8 containing 1 mM ethylenediaminetetraacetic acid disodium salt) and 20 µl of 
10 mM Ellman’s solution was added to the mixture [29]. The absorption spectrum of the solution 
was recorded with a UV-VIS spectrophotometer (Specord 200, Analytic Jena, Jena, Germany) 
after a reaction time of 20 min (T = 37 °C during the reaction). The thiol content of the solution 
was calculated from the absorption peak at 405 nm, using the calibration curve determined for 
ACC (ε = 12622 M-1 cm-1).  The thiol content determined includes the number of thiol groups both 
on the polymer and on the stabilizing agent. 
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2.3. Kinetics of swelling 
The water absorption capacity of the ThioPASP gels was determined gravimetrically. The 
ThioPASP gels were prepared in a syringe. The ThioPASP polymer was dissolved in PBS and 1 M 
oxidant solution was than added. The final concentration of both the polymer and the 1 M oxidant 
solution was 20% w/w. After gelation, the gel was pushed out of the syringe, cut into four equal 
parts (for the four parallel measurements) and dried in vacuum at 30 °C to constant weight. The 
weights of the discs were measured and they were placed into distilled water at room temperature. 
The discs were taken out of the water after defined time periods, the surplus water was removed 
by blotting and the weights of the gels were measured gravimetrically [27]. 
 
2.4. Morphology/internal structure 
The hydrogels containing 10% w/w ThioPASP and antioxidant swollen in PBS were freeze-
dried and sputter-coated with gold (Bio-Rad SC 502, VG Microtech, Uckfield, United Kingdom). 
The internal structure of the ThioPASP networks was determined by scanning electron microscopy 
(SEM) (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan). 
 
2.5. Rheology 
The rheological properties were studied with a Physica MCR101 rheometer (Anton Paar, Graz, 
Austria). The measuring device was of cone and plate type (diameter 25 mm, gap height in the 
middle of the cone 0.046 mm, and cone angle 1°). To find a standard, reproducible oxidant 
circumstance, in our tests we used sodium bromate as model oxidant to simulate the oxidative state 
of the eye, which can help to study the gelation properties of our polymer, and compare the effect 
of the applied antioxidant on it. ThioPASP polymers containing different antioxidants were 
dissolved in PBS at three concentrations and the polymer solutions were mixed with 1 M oxidant 
on the plate of the rheometer to simulate the contact with the eye and the investigation was started 
immediately to follow the gelation from the beginning of the contact. The final polymer 
concentrations were 5, 7 or 10% w/w and the final concentration of the oxidant was 20% w/w. 
When the mucoadhesion was studied, the polymer solutions were mixed with the mucin dispersion 
in PBS before the addition of the oxidant (the final mucin concentration in the mixtures was 
5% w/w and both the final polymer and oxidant concentrations were identical to those of the 
samples prepared without mucin). Each measurement was carried out on a freshly-made sample 
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and was started immediately after mixing of the compositions. The gelation of the ThioPASP 
polymer was followed at a constant frequency of 1.0 Hz at a constant strain of 1% at 25 °C. In our 
investigation, the gelation time was defined as the time at which a maximum could be observed in 
the curve of the differential with respect to time [27] (differential curves are not presented in the 
paper). Viscoelastic character was determined by frequency sweep tests after the gelation, with a 
strain of 1% at 25 °C. Storage modulus (G’) was determined over the angular frequency range 
from 0.1 to 100 s-1. The strain value (1%) used in the measurements was in the range of the linear 
viscoelasticity of the gels [27]. 
 
2.6. Adhesion test 
Adhesion tests were performed with a TA-XT Plus (Texture analyzer, ENCO, Spinea, Italy) 
instrument equipped with a 1 kg load cell and a cylinder probe with a diameter of 1 cm. Samples 
containing different amounts of ThioPASP were dissolved in PBS and 20% w/w of 1 M oxidant 
solution. 20 mg of the sample was attached to the cylinder probe and was gelated for 10 min. The 
sample was then placed in contact with a filter paper disc wetted with 50 µl mucin dispersion 
(8% w/w, prepared in simulated lachrymal fluid (pH = 7.4) ) or with simulated lachrymal fluid, 
and  a 2500 mN preload was applied for 3 min (the compression speed was 2.5 mm min-1). The 
cylinder probe was then moved upwards to separate the sample from the substrate at a prefixed 
speed of 2.5 mm min-1. 10 parallel measurements were carried out [30]. The work of adhesion (A, 
mN mm) was calculated as the area under the “force versus distance” curve (AUC) [27, 31, 32]. 
 
2.7. Drug release 
The drug release profile of SD was determined with a vertical Franz diffusion cell system 
(Hanson Microette Plus TM, Hanson Microette TM Topical &Transdermal Diffusion Cell System; 
Hanson Research Corporation, Chatsworth, CA). 300 µl of formulation containing 7% w/w 
polymer solution with 0.1% w/w SD and 20% w/w oxidant solution in final concentration was 
placed on a Porafilm membrane filter (pore size 0.45 	m, Porafil; Machenerey-Nagel, Germany, 
and Pall Life Sciences, Washington, NY) impregnated with pH = 7.4 buffer solution. The two 
solutions were mixed on the membrane filter as a donor phase. 7 ml of PBS (pH = 7.4) was used 
as acceptor phase and thermostated at 35 °C. Measurements were performed for 24 h and five 
parallel measurements were carried out. 0.8 ml samples were taken from the acceptor phase by the 
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autosampler and replaced with fresh PBS. The released SD was quantified by UV 
spectrophotometry (Helios α Thermospectronic UV-spectrophotometer v4.55, Unicam; Thermo 
Fisher Scientific, Waltham, MA) at 275 nm [27, 33]. 
 
2.8. Statistical analysis 
The results of stability, swelling, mucoadhesion, and drug diffusion were also analyzed statistically 
with GraphPad Prism version 5 software. Two-way ANOVA analysis was applied with Bonferroni 
post-tests.  A level of p≤0.05 was taken as significant, p≤0.01 as very significant,and p≤0.001 as 
highly significant. 
 
3. Results and discussion 
3.1. Stability of polymers 
The stability of components in a dosage form is a crucial issue, and must therefore be investigated 
during formulation development. As earlier studies [8, 9] showed, thiolated polymers have poor 
stability in aqueous solutions at pH > 6 because of the atmospheric oxidation of thiol groups 
resulting in the formation of inter- and intramolecular disulfide bonds. In ocular therapy, aqueous 
formulations are preferred, and the stability of the components in this medium is therefore a very 
critical factor.  
In our work, different reducing agents were used to stabilize aqueous ThioPASP formulations and 
the effects of additives and the storage conditions of the formulations were investigated. The 
concentration of the antioxidant were set at a minimum, 1% w/w reducing agent referring to the 
polymer amount was applied. In case of ophthalmic formulation, the low concentration of additives 
is important to avoid the irritation and other side effects.  
The results can predict the time within which the dosage form can be safely used after the 
preparation of the solution. Aqueous polymer solutions were stored frozen (-20 °C), in a 
refrigerator (4 °C), and at room temperature (25 °C), and the percentage of free thiol groups was 
determined at given times (0, 1, 7, 14 and 28 days). The decrease in the number of free thiol groups 
during storage is shown as a function of time in Fig 1. 
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The changes in the free thiol content during storage indicate that the polymer solutions are stable 
within 24 h (the free thiol content is > 90%), but the thiol content decreases significantly after the 
first day, independently of the storage temperature. The most marked fall can be seen at 25 °C 
(There were no significant differences between the formulations at this storage temperature, 
p> 0.05 in each cases).  
Although the thiol groups include those of small molecular antioxidants and of the polymer, the 
results can give a guideline for choosing the proper additive. ThioPASP/ACC and ThioPASP/GSH 
can preserve the free thiol content at above 90% for 7 days while thiol content of formulations 
containing DTT highly decreases. Without a deeper analysis of the mechanism of the antioxidant 
effect, ACC and GSH are recommended for the stabilization of ThioPASP because the major part 
of the thiol groups remain reduced (free thiol content of ThioPASP/GSH is significantly, and very 
significantly higher than that of ThioPASP/DTT on 14 and 28 days respectively, at 4 °C). In 
ThioPASP/DTT samples, oxidation of thiol groups occurs in a large extent and we can assume that 
the thiol groups either of the antioxidant or the polymer, or even of both components are strongly 
oxidized after one day. 
 
3.2. Swelling 
The swelling properties of a dosage form must be taken into consideration in each process where 
water uptake can take place, such as drug release and mucoadhesion (where the sample meets a 
hydrated surface such as a mucin dispersion or the mucosa). The swelling of non-hydrated or 
partially-hydrated samples can affect the interpenetration, the entanglement of the polymer chains 
and the formation of chemical interactions.  
Gravimetry was used to determine the swelling properties of ThioPASP gels. Figure 1 shows 
the water-uptake capacity (%S), calculated from the following equation [34]  
  
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 (1) 
where M0 is the mass of the dry gel (g) and Mt is the mass of the swollen gel (g). This value (% S) 
gives information about the water-uptake capacity of the polymer.  
During the 6 h measurements, the swollen ThioPASP/DTT and ThioPASP/ACC polymer discs 
remained mechanically stable due to the formation of disulfide linkages between the polymer 
chains.  
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Figure 2 indicates that ThioPASP/DTT has a lower water-uptake capacity than that of 
ThioPASP/ACC. The ThioPASP/GSH polymer disintegrated after 1 h, and therefore the final 
water uptake of these gels cannot be taken into consideration. The initial parts of the curves of 
ThioPASP/ACC and ThioPASP/GSH reveal the similar swelling properties of these hydrogels, 
although the final values cannot be compared because of the partial disintegration of the latter. The 
tentative explanation of these results that during the cross-linking of ThioPASP/ACC and 
ThioPASP/GSH samples polymer-polymer disulfides, dimers of the stabilizing agent and 
asymmetrical disulfides consisting of polymer chains and ACC or GSH can also be formed 
simultaneously. In the case of ThioPASP/DTT, intramolecular disulfide formation of DTT is 
preferred leading to smaller amount of asymmetrical polymer-DTT disulfides. This results in a 
lower cross-linking density of ThioPASP/ACC and ThioPASP/GSH samples as asymmetrical 
disulfides do not act as netpoints, while in the case of ThioPASP/DTT samples mostly polymer–
polymer disulfides are formed. Accordingly, the swelling results for the first 60 minutes are similar 
for ACC and GSH containing samples (no significant differences up to 60 min), while 
ThioPASP/DTT had a higher number of netpoints, resulting in a smaller degree of swelling (there 
are highly significant difference between ThioPASP/ACC and ThioPASP/DTT after 30 min).  
 
3.3. Morphology  
The ThioPASP/GSH polymer gel fell apart during the swelling measurement, while 
ThioPASP/DTT and ThioPASP/ACC remained coherent. The difference in the internal structures 
of the gels can be clearly seen in the SEM pictures (Fig. 2). ThioPASP/DTT and ThioPASP/ACC 
have a continuous structure with rather large pores, while ThioPASP/GSH shows a more porous 
structure. The poor mechanical stability is not preferred at the application site, because it can result 
in unpredictable drug release, residence time and bioavailability. 
 
3.4. Rheology 
The gelation time can be  critical in case of an in situ gelling ophthalmic formulation: too fast 
gelation can lead to inadequate spreading on the surface and foreign body sensation to the patient, 
while an elongated gelation results in a too fast elimination by tear drainage and blinking. 
ThioPASPs are redox-sensitive systems, therefore they display a solution-to-gel transition in the 
presence of oxidizing agent. The eye is highly exposed to oxidative stress, the most important 
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oxidants are reactive oxygen species (ROS) and reactive nitrogen species (RNS). The 
concentration of the ROS/RNS in the eye is very high due to its exposition to several environmental 
factors like high pressure of oxygen, light exposure, ultraviolet and ionizing radiation, foreign 
chemicals and pathogenic microbes, which can also produce oxidant species [35]. In in vivo 
circumstance, ThioPASP solutions can probably gelify thanks to this oxidative effect of the eye, 
but in our test we used sodium bromate as model oxidant to simulate this state. 
The gelling process can be traced by changes of the storage modulus. The storage modulus (G’) 
represents the elastic behaviour of the sample, therefore shows the changes in the gel state. In 
previous work [27], we proved that mucin plays an important role in gelation, by decreasing the 
gelation time and increasing the final value of the storage modulus. We therefore determined the 
gelation time of the ThioPASP/DTT, ThioPASP/GSH and ThioPASP/ACC polymers at different 
polymer concentrations (5, 7 and 10% w/w) to assign the effects of the antioxidants to the gelation 
time and gel strength (Fig. 3).  
At low polymer concentration (5% w/w), no gelation was observed in the case of 
ThioPASP/DTT or ThioPASP/ACC, while ThioPASP/GSH showed moderate gelation after 5 min 
in mucin free-samples. After the addition of mucin, a weak gel structure evolved in 
ThioPASP/GSH and ThioPASP/ACC samples at the beginning of the measurement, but in the case 
of ThioPASP/DTT only after 15 min. At medium polymer concentration (7% w/w), 
ThioPASP/DTT and ThioPASP/GSH were able to form a gel structure without mucin, but 
ThioPASP/ACC did not start to gelify. In the presence of mucin ThioPASP/GSH and 
ThioPASP/DTT samples showed a transformation from a sol to a gel within 10 min. At high 
ThioPASP concentration (10% w/w), in both the mucin-containing and the mucin-free samples, 
ThioPASP/DTT, ThioPASP/GSH and ThioPASP/ACC formed a gel structure within 5 min.  
The nature of the reducing agent influences the gelation time in the mucin-containing and 
mucin-free samples at low (5% w/w) and medium (7% w/w) polymer concentration. Increase of 
the ThioPASP concentration decreased the gelation time. The ThioPASP/DTT had the longest 
gelation time at all concentrations, which was decreased by the addition of mucin, suggesting the 
strongest antioxidant (reducing) effect against the oxidizing agent. In the mucin-free samples, the 
ThioPASP/ACC sample at low polymer concentrations (5 and 7% w/w) did not gelify, while at 
10% w/w ThioPASP concentration the gelation was as fast as in the case of ThioPASP/GSH. In 
the mucin-containing samples, immediate gelation could be measured at low polymer 
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concentrations (5 and 7% w/w), which is indicated by the elevated G’ values. Our results 
demonstrate that the gelation process is effected by the type of the oxidizing agent, the polymer 
concentration, and the presence of mucin. At 10% w/w polymer concentration, the gelation 
occurred within 5 min and did not immediately. In our previous work we presented wash away 
and adhesion test as well where this type of polymers showed high resistance against the simulated 
elimination mechanism even in sol state of the system [27]. In view of this earlier statement, 
probably a thin layer of the polymer solution can remain on the ocular surface which does not 
cause foreign body sensation to the patient, and after the total gelation provide a long-lasting effect. 
The frequency sweep test was started after full gelation. Figure 5 depicts the variation in G’ 
with angular frequency for the ThioPASP/DTT, ThioPASP/GSH and ThioPASP/ACC 
formulations with mucin-containing and mucin-free samples.  
At all polymer concentrations and in all cases (mucin-containing and mucin-free), each sample 
showed a frequency-independent storage modulus. At low polymer concentration (5% w/w), there 
was no significant difference between the mucin-containing and mucin free-samples in the 
ThioPASP/DTT samples. In the cases of ThioPASP/GSH and ThioPASP/ACC a significant 
increases in G’ could be seen after the addition of mucin. At medium polymer concentration 
(7% w/w), a significant difference could be observed only in the case of ThioPASP/ACC between 
the mucin-containing and mucin-free samples. The values of G’ of ThioPASP/DTT and 
ThioPASP/GSH samples were not higher in the presence of mucin. The increase of the G’ values 
in the presence of mucin suggests an interaction between the polymer and the mucin chains. At 
the highest polymer concentration, there was a negligible difference between the G’ values with 
and without mucin, which indicates the formation of a stiff gel structure independently of the 
presence of mucin. Furthermore, a very slight decrease was observed in the case of the mucin-
containing samples; we believe that mucin-polymer interactions are still present at this 
concentration, but the gel structure weakens due to the heterogeneity of the mucin dispersion.  
The rheological mucoadhesion measurements demonstrated that the ThioPASP/DTT sample 
does not have strong mucoadhesive properties and possibly does not favour the formation of 
covalent bonds between thiolated polymers and mucin glycoproteins via thiol/disulfide exchange 
reactions. ThioPASP/GSH and ThioPASP/ACC are mucoadhesive up to 7% w/w polymer 
concentration, suggesting that ThioPASP/DTT has a strong reducing capability which hinders the 
chemical interaction of ThioPASP and mucin, while GSH and ACC do not impede disulfide 
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formation between the polymers, while providing sufficient atmospheric stability of ThioPASP at 
the same time.  
 
3.5. Adhesion tests 
The mucoadhesion of the ThioPASP samples was characterized by tensile tests, which involved 
the measurement of the force of detachment (F, mN) and the total work of adhesion (A, mN.mm), 
the latter calculated from the area under the force–distance curve [36]. The measured values of F 
and A are depicted in Fig. 6. 
The values of F in the case of the ThioPASP/DTT sample increased continuously as the 
concentration was elevated until 7% w/w polymer concentration, above which a plateau was 
observed. At 3, 5 and 7% w/w polymer concentrations, an increase in polymer concentration was 
accompanied by an increase in the number of free thiol groups at the interface, which are able to 
form disulfide bonds with mucin. At high polymer concentration, the ThioPASP gel is strongly 
cross-linked by both chemical and physical bonds and entanglements. The number of accessible 
free thiol groups on the polymer is therefore decreased and the interpenetration of the polymer and 
the mucin is limited. Similar observations can be seen in the case of the A values. At high polymer 
concentration (10% w/w), the low number of free thiol groups and the highly cross-linked structure 
limited the interpenetration of the gel into the mucin layer, resulting in a plateau in the A curve. 
As we described previously (swelling), in the presence of DTT as reducing agent, the higher 
number of polymer–polymer disulfide linkages and the shorter free chain length decrease the 
interpenetration of the polymer chains of mucin and the sample.  
The F curve of ThioPASP/GSH increased continuously with increasing polymer concentration. 
At 7% w/w polymer concentration, a weak gel formed, resulting in an easier rupture during the 
tensile test, and thus the cessation of adhesion is mainly due to the cohesive failure of the gel. In 
spite of the weak structure, the number of free thiol groups increased as the ThioPASP 
concentration was elevated, resulting in increases in the F and A values.  
The ThioPASP/ACC sample at low polymer concentrations (3 and 5% w/w) displayed a 
constant F value because at those concentrations the sample is in a sol state and the lack of cohesion 
results in a poor mucoadhesive character. At 7% w/w polymer concentration, gelation occurred, 
as shown in the rheological experiments, resulting in the significant increase in F values, but at 
higher polymer concentration (10% w/w) the number of free thiol groups did not increase at the 
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surface, which resulted in a plateau in the F curve. In the case of A at high polymer concentration 
a continuous increase in the values can be seen thanks to the increasing interpenetration.  
The results suggest the existence of an optimum polymer concentration for interpenetration and 
the formation of mucoadhesive interactions. Our results show that ACC can be a potential 
stabilizing agent (in most cases F and A values are significantly higher compared with those of 
ThioPASP/GSH and ThioPASP/DTT); the cross-linked structure formed provides considerable 
mucoadhesion, because a sufficient amount of free thiol groups is available to establish a strong 
polymer–mucin interaction, and the atmospheric stability of the ThioPASP in solution is also 
sufficient when this antioxidant is used.  
 
3.6 Comparison of results of the rheology and adhesion tests 
The results of rheological measurements and adhesion tests can be correlated easily by the 
calculation of synergism parameters of rheology (	can be determined by dynamic oscillatory 
rheometry, calculated as follows [27, 37]:  
   	 	 	  (2) 
where G’ is the storage modulus of the systems.  
If the calculated synergism parameters are negligible, it is reasonable to use the relative 
rheological synergism parameters ( , which express the relative increments in viscoelasticity 
with regard to the polymer and mucin solutions alone [27, 37]:  
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In the case of adhesion tests, the normalized mucoadhesion parameters (∆AUC/AUC) can be 
used, calculated as follows [38]:  
 ./01./0  	 ./0(./02 ./02⁄      (4) 
where AUCm is the work of adhesion in the presence of mucin and AUCb is the work of adhesion 
of blank measurements (with simulated lachrymal fluid).  
The rheological measurement of mucoadhesion is a bulk method, where the polymer and the 
mucin are mixed, while in the case of adhesion tests mucoadhesion is measured at the interface 
between the polymer and the mucin. The mucoadhesion occurs at the interfacial layer, the 
thickness of which depends on the interdiffusion between the mucin and the polymer molecules. 
Figure 7 presents the calculated absolute and relative synergism parameters of G’ at an angular 
frequency of 1 s-1. The calculated normalized mucoadhesion parameters are depicted in Fig. 8.  
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The ThioPASP/DTT formulations in the bulk rheological method did not show synergism with 
mucin; moreover, increase of the polymer concentration further decreased the synergism, resulting 
in more and more negative ∆G’ and very low ∆G’rel values. However in the adhesion tests as 
surface method, mucoadhesion could be observed which increased as the concentration was 
elevated, but the normalized AUC/AUC values indicate that the higher netpoint density of the 
ThioPASP/DTT samples hinders the formation of new polymer–mucin interactions as the 
concentration increases.  
ThioPASP/GSH at low polymer concentration was mucoadhesive in the bulk method, but with 
increase of the polymer concentration its mucoadhesivity decreased. As compared with the DTT-
stabilized samples, the adhesion tests indicated weak synergism with mucin, which can be 
explained by its weak cohesivity and resistance against the tensile load.  
Up to 7% w/w polymer concentration, the ACC-stabilized formulation displayed marked 
synergism as compared with the other two types of formulation. At 7% w/w ThioPASP/ACC, the 
gel structure was formed, which can provide optimum mucoadhesion proved by both rheological 
experiments and adhesion tests (high values of ∆G’, ∆G’rel and ∆AUC/AUC).  
 
3.7. Drug release 
SD release from the ThioPASP/DTT, ThioPASP/GSH and ThioPASP/ACC gels (as optimum, 
7% w/w polymer concentration) was determined with a vertical Franz diffusion cell system for 
24 h (Fig. 9).  
The results indicate that the ThioPASP/GSH gel releases the highest amount of SD (~80%) 
after 24 h, while ThioPASP/DTT and ThioPASP/ACC release lower amounts of SD and there is 
no significant difference between the latter two. These results correspond with the results of the 
swelling and SEM measurements. The very porous ThioPASP/GSH fell apart after 1 h, and 
therefore SD is able to diffuse easier out from the gel. ThioPASP/DTT and ThioPASP/ACC have 
a more cohesive structures than that of ThioPASP/GSH, resulting in a slower diffusion of the 
active component.  
The kinetics of the drug release was determined with the Korsmeyer-Peppas equation as 
follows:  
 

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where Mt and M∞ are the amounts of drug released at time t and at equilibrium, respectively, while 
 is the fraction of drug released, k is the kinetic constant and n is the release exponent 
describing the mechanism of the release [39]. These values were determined from the equation of 
the power law fitted to the curve of the amount of drug released (% w/w) against time (min) and 
are showed in Table 1 [27]. 
 
The fitting results reveal that all the samples undergo non-Fickian diffusion, because the n 
values are between 0.5 and 1. These results correspond to those of the swelling measurements, 
where non-Fickian swelling of the gels was also found. The non-Fickian release mechanism is a 
swelling-controlled mechanism, where simultaneous water uptake and active ingredient desorption 
occur.  
It can be concluded that ThioPASP/GSH has the fastest release (significantly higher values after 
5 hours compared with ThioPASP/DTT and ThioPASP/ACC), but this type of formulation cannot 
be used in controlled release because of the disruption of the gel. Although ThioPASP/DTT and 
ThioPASP/ACC release lower amounts of SD, their release profile can be designed thanks to their 
stable structures and these formulations can provide sustained, continuous release.  
 
4. Conclusions 
In the present work, three types of reducing agents were used to ThioPASP. The aim was to 
find an optimum stabilizing agent which can increase the stability of aqueous formulations and 
ensure an appropriate gel structure for mucoadhesion and drug release. ThioPASP gels were first 
characterized by swelling and rheological methods, followed by the determination of their 
mucoadhesion (rheological and tensile tests) and drug release.  
The results suggest that the stability of the polymer solution containing antioxidants is sufficient 
for one day. ThioPASP stabilized with DTT showed fast swelling and drug release, but as 
compared with the other samples its mucoadhesion is rather weak. ThioPASP stabilized with GSH 
has the weakest cohesive properties, resulting in fast, but rather uncontrolled drug release and its 
mucoadhesion is only slightly stronger than that of ThioPASP/DTT. ACC stabilized ThioPASP 
has an optimum cross-linked structure with free thiol groups ensuring polymer–mucin interactions, 
resulting in the best mucoadhesive properties. Its swelling properties are than those of the other 
two formulations, which also plays an important role in mucoadhesion and drug release.  

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It can be concluded that the optimum stabilizing agent is ACC. At 7% w/w ThioPASP/ACC 
concentration gel structure can be formed which can be base for a controlled released system and 
this structure can provide optimum mucoadhesion.  
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Figure captions 
 
Fig. 1 Changes in free thiol content of ThioPASP polymer solutions during storage with various 
temperature of storage: a) -20 °C, b) 4°C and c) 25 °C. The stabilizing agents were (
)ThioPASP/DTT; ( ) ThioPASP/GSH; ( ) ThioPASP/ACC. 
 
Fig. 2 Swelling kinetics of ThioPASP gels: ( ) ThioPASP/DTT; ( ) ThioPASP/GSH; ( ) 
ThioPASP/ACC. 
 
Fig. 3. SEM pictures of lyophilized swollen ThioPASP gels: a) ThioPASP/DTT, 
b) ThioPASP/GSH and c) ThioPASP/ACC. 
 
Fig. 4. Increase in the storage modulus of the ThioPASP solutions upon oxidation: ( ) 
ThioPASP/DTT; ( ) ThioPASP/GSH and ( ) ThioPASP/ACC; with and without (open symbol) 
mucin at (a) 5, (b) 7 and (c) 10% w/w polymer concentrations. 
 
Fig. 5. Frequency sweep test of ThioPASP gels: ( )ThioPASP/DTT; ( ) ThioPASP/GSH and ( ) 
ThioPASP/ACC; with and without (open symbol) mucin at different polymer concentrations (a) 
5, (b) 7 and (c) 10% w/w. 
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Fig. 6. a) Adhesive force (F) and b) adhesive work (A) as functions of ThioPASP concentrations: 
( )ThioPASP/DTT; ( )ThioPASP/GSH; ( )ThioPASP/ACC.  
 
Fig. 7. The calculated a) absolute and b) relative synergism parameters of G’ in rheological 
measurements. 
 
Fig. 8. The calculated normalized mucoadhesion parameters of work of adhesion in tensile test 
measurements. 
 
Fig. 9. Release of SD from ThioPASP gels at 7% w/w polymer concentration: ( ) ThioPASP/DTT; 
( ) ThioPASP/GSH; ( ) ThioPASP/ACC. 
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